Gemcabene - Gemphire Therapeutics

Drug Profile

Gemcabene - Gemphire Therapeutics

Alternative Names: CI-1027; Gemcabene calcium; PD 0072953; PD 072953

Latest Information Update: 21 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Emory University; Gemphire Therapeutics; Pfizer
  • Class Antihyperlipidaemics; Caproates; Small molecules
  • Mechanism of Action Acetyl-CoA carboxylase inhibitors; Apolipoprotein C-III inhibitors; C-reactive protein inhibitors; CCR2 receptor antagonists; CCR5 receptor antagonists; Lipoprotein A inhibitors; Sulfatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypercholesterolaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypercholesterolaemia; Hyperlipoproteinaemias; Hypertension; Hypertriglyceridaemia; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Osteoarthritis

Most Recent Events

  • 08 Nov 2018 Gemphire Therapeutics plans an end of phase II meeting with the US FDA in 2019
  • 13 Aug 2018 USFDA requested Gemphire Therapeutics to provide additional data regarding the partial clinical hold
  • 10 Aug 2018 Emory University and Gemphire Therapeutics terminate phase II trial in Non-alcoholic fatty liver disease (In adolescents) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top